Objective: To evaluate the weight loss efficacy, safety and tolerability of taranabant, a CB1R inverse agonist, in obese and overweight patients. Design: Multicenter, double-blind, randomized, placebo-controlled study. Subjects: Patients X18 years old, BMI 27-43 kg m À2 , were randomized to placebo (n ¼ 209) or taranabant 0.5 mg (n ¼ 207), 1 mg (n ¼ 208) or 2 mg given orally once daily (n ¼ 417) for 52 weeks. Measurements: Key efficacy measurements included body weight (BW), waist circumference (WC), lipid endpoints and glycemic endpoints. Results: Based on a last observation carried forward analysis of the all-patients-treated population, mean change in BW for taranabant 0.5, 1, and 2 mg and placebo was À5.4, À5.3, À6.7 and À1.7 kg, respectively (Po0.001 for all doses vs placebo). The proportions of patients who lost at least 5 and 10% of their baseline BW at week 52 were significantly higher for all taranabant doses vs placebo (Po0.001 for all doses). Reductions in WC, percentage of body fat, and triglycerides were significant for taranabant 2 mg and in triglycerides for taranabant 1 mg vs placebo. There was no effect of taranabant vs placebo on other lipid or glucose-related endpoints. Incidences of adverse experiences classified in the gastrointestinal (diarrhea and nausea), nervous system (dizziness/dizziness postural), psychiatric-related (irritability and anger/aggression) and vascular (flushing/hot flush) organ systems were higher and statistically significant in the taranabant 2-mg group compared with the placebo group. Irritability was higher and statistically significant in all taranabant groups compared with the placebo group. Conclusion: All three doses of taranabant-induced clinically meaningful and statistically significant weight loss. Incidences of adverse experiences in organ systems known to express CB1R were higher in taranabant groups.
Introduction
Pharmacotherapy, as part of a comprehensive weight loss program, is adjunctive to lifestyle interventions. 1, 2 However, currently marketed medications have limited efficacy and a variety of safety and tolerability issues. 3, 4 The endocannabinoid system, including the cannabinoid-1 receptor (CB1R), is a new target for weight loss medications. The first-in-class drug acting within the endocannabinoid pathway, rimonabant, promotes weight loss in both laboratory animals and humans through antagonism of the CB1R. [5] [6] [7] [8] [9] Rimonabant taken at a daily dose of 20 mg leads to statistically significant weight loss and reduces weight regain compared with placebo for as long as 2 years. 10 In the published rimonabant studies, gastrointestinal and psychiatric adverse experiences were reported to have increased incidence compared with placebo. Taranabant, an inverse agonist, has the ability to inhibit CB1R activity in the absence or presence of an agonist. In the presence of an agonist, taranabant competitively antagonizes the agonist effect.
11 A 12-week dose range finding study in obese adults showed that taranabant taken at a daily dose of 0.5, 2, 4 or 6 mg produced clinically meaningful and statistically significant weight loss compared with placebo. 11 As taranabant 0.5 mg showed greater weight loss than placebo at 12 weeks and had better tolerability than doses 2 mg and higher, this study was designed to test the hypothesis that one or more of the lower range doses of taranabant decreases body weight more than placebo over 52 weeks and is well tolerated. , but only if they had the obesity-related comorbidities of hypertension, dyslipidemia or sleep apnea. Patients must have maintained a stable body weight ( ± 3 kg) for at least 3 months before entry. Exclusion criteria were a history or presence of a major psychiatric disorder including but not limited to schizophrenia, other psychotic disorders, major depression, bipolar disorder, generalized anxiety disorder, personality disorder and eating disorder (for example, anorexia nervosa or bulimia). However, patients with a history of mild depression, who were asymptomatic at the time of screening/randomization, including those who were on a single medication for the treatment of their depression, were allowed to participate. Patients with a Patient's Health Questionaire-9, (PHQ-9) 12 score 412 or a score of 40 on question 9, which probes for suicidality, before randomization were excluded. Other exclusion criteria included hypertension (systolic/diastolic blood pressure 4160/ 4100 mm Hg), diabetes mellitus; and any other clinically significant disorder including cardiovascular, pulmonary, hepatic, renal, gastrointestinal, neurological, malignancy o5 years, or endocrine diseases with the exception of patients with stably treated hypothyroidism as determined by a normal TSH. Patients with a history of seizures or at high risk of developing seizures were also excluded. Patients were excluded if they had undergone surgical treatment for obesity within the past 5 years. Patients on potent or moderate inhibitors of CYP3A4 (taranabant is metabolized by CYP3A4) 13 or systemic corticosteroids were excluded.
Methods

Patients
Patients who smoked cigarettes or used products containing nicotine within 6 months before study initiation, or planned to over the course of the study were excluded. The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. The study was approved by an institutional review board or independent ethics committee and all patients provided written informed consent.
Study design
The study included a 2-week single-blind placebo run-in period with dietary/activity counseling, a 52-week treatment period, and a 4-week post-treatment follow-up period. Clinic visits occurred at 4-week intervals during the treatment period and intervening patient telephone contacts were made by study site staff to enhance patient retention. Patients were randomized, in a blinded manner, using a computer-generated random allocation schedule to 0.5, 1 or 2 mg taranabant, or placebo given as a capsule, orally once daily, in a 1:1:2:1 ratio.
Initial dietary assessment and counseling were provided by a registered dietitian at the start of the placebo run-in period. The recommended diet was 25% lower in kcal than weight maintenance requirements and contained 55-60% carbohydrate, 10-20% protein, and not more than 30% fat, with a minimum daily caloric intake of 1200 kcal. Dietary counseling and review of daily food intake and physical activity records were also performed at each visit throughout the study. All patients were encouraged to increase their level of physical activity based on their current activity and health status.
Patients who were at least 75% compliant (as defined by capsule count) and who did not gain weight over the diet/ activity run-in period, and who met all entry criteria, were randomized into the study. Medication compliance was assessed by capsule count at each subsequent visit.
Measurements
The primary efficacy endpoints were absolute change in body weight from baseline (last measurement before start of double-blind study drug) and the proportion of patients who lost at least 5 or 10% of their baseline body weight at week 52.
Secondary endpoints were change (or percent change as appropriate) from baseline in waist circumference, percent body fat measured by dual energy X-ray absorptiometry, fasting plasma glucose, insulin, insulin sensitivity, fasting lipid profile (triglyceride, total cholesterol, high-density lipoprotein cholesterol (HDL-C), non-HDL-C, low-density lipoprotein cholesterol (LDL-C)), blood pressure, adiponectin and high sensitivity C-reactive protein. Blood samples were analyzed at a central laboratory (Quest Diagnostics Clinical Trials Van Nuys, CA, USA and Quest Diagnostics Limited Heston, UK). The Patient Health Survey (SF36/Acute v2) 14 and
Impact of Weight on Quality of Life (IWQoL) 15 were used to evaluate the effect of treatment on quality of life. Safety assessment included collection of adverse experiences, physical examinations (including neurological examinations), vital signs and self-administered patient-reported outcome questionnaires for the evaluation of cognitive/ neuropsychomotor performance, mood and signs or symptoms of depression (Digital Symbol Substitution Test, 16 Profile of Mood State brief form (POMSb), 17 and PHQ-9. The PHQ-9 was incorporated into the protocol as a screening and monitoring Taranabant Low-Dose Study J Proietto et al tool to assess depression-related mood changes and suicidal ideation. Patients who developed a psychiatric adverse experience that was not considered an emergency were referred to a qualified mental health professional for evaluation. Patients were administered the full PHQ 18 following any reported psychiatric adverse experiences. Adjudication of possibly suicide-related adverse events (PSRAEs) was retrospectively performed according to an FDA guidance for exploring suicidality (suicide ideation and behavior) in placebo-controlled clinical trials. 19 Narratives for these PSRAEs were written and adjudication of these events was performed by an independent external adjudication committee (Columbia University), which used the Columbia Classification Algorithm of Suicide Assessment (C-CASA). 20 Laboratory safety assessments included blood chemistry, hematology, urinalysis and urine b-hCG pregnancy testing (in women of childbearing potential). Electrocardiograms were performed and evaluated locally.
Statistical analyses
Efficacy analyses were performed on the all-patients-treated population consisting of all randomized patients who received at least one dose of study drug and who had valid measurements both at baseline and at least one posttreatment time point. Change in body weight (primary endpoint) was assessed using an analysis of covariance model that included terms for treatment, geographical region, baseline body weight and weight loss during the 2-week placebo run-in period. The proportions of patients who lost at least 5 or 10% of their baseline body weight were analyzed using logistic regression models with the same terms as used in the analysis of covariance model. Missing data at week 52 was imputed using the last post-baseline observation carried forward method. All statistical tests were two-sided with an a-level of 0.05.
Secondary efficacy endpoints were analyzed using analysis of covariance models similar to that of body weight with the addition of a term for baseline value pertaining to the endpoint of interest. Multiplicity adjustment was applied to the comparisons of the primary and key secondary endpoints. The primary weight loss hypothesis consisted of an ordered family of comparisons. After the significance of the mean weight loss comparison between taranabant 2 mg and placebo was established, all other comparisons were assessed using a closed testing procedure for the remaining primary endpoints and all three families (weight-related, lipid and glycemic) of key secondary endpoints. Each endpoint was assessed separately by stepping down the doses of taranabant (2 mg through 0.5 mg), as well as, the prespecified testing order within a family of end points. The prespecified order of testing within the weight-related family was change in waist circumference followed by percent body fat from baseline at week 52. The prespecified order of testing within the lipidrelated family was percent change in triglycerides, HDL-C, non-HDL-C, LDL-C from baseline at week 52. The prespecified order of testing within the glycemic-related family was change in insulin, insulin sensitivity as measured by quantitative insulin sensitivity check index (QUICKI) 21 and fasting plasma glucose from baseline at week 52. No multiplicity adjustments were made for the remaining secondary endpoints. Safety was assessed in the all-patients-as-treated population (APaT) consisting of all patients who took at least one dose of study drug. Inferential testing of pre-specified adverse experiences of interest was performed using Fisher's Exact Test and the associated 95% confidence interval computed using the Wilson's Score Method to compare the proportion of patients with the adverse experience in the drug group versus the placebo group.
The terms 'numerically higher' or 'numerically lower' are used to describe results where differences from placebo did not reach statistical significance, but are potentially clinically meaningful.
Results
Baseline characteristics and patient disposition A total of 1481 patients were screened and 440 (29.7%) were excluded based on laboratory values (n ¼ 105; 23.9%), the diabetes mellitus exclusion criterion (n ¼ 49; 11.1%), failure to meet the BMI inclusion criterion (n ¼ 42; 9.5%), patient withdrew consent (n ¼ 69; 15.7%), or other reason (n ¼ 175; 39.8%). The remaining 1041 (70.3%) patients were randomized 1:1:2:1 to once-daily treatment with double-blind taranabant 0.5, 1, or 2 mg or placebo for 52 weeks. The primary therapy period was between 24 October 2006 and 22 January 2008. Of the 1041 patients randomized, 1040 received at least one dose of study medication and 693 (66.7%) completed the study (Table 1) . A total of 347 (33.3%) patients discontinued the study drug before completion of the trial; of these, 122 (35.2%) agreed to continue in the study off-drug. Of these latter 122 patients, 99 (81.1%) completed the study off study drug and 6 (4.9%) resumed study drug before week 52. Of those six patients, two subsequently discontinued before completion of the trial and four completed the trial. The reasons for study discontinuation by dose group are shown in Table 1 .
Treatment groups were generally similar with respect to patient demographics, baseline characteristics and biochemical measures (Tables 2 and 3 ). The overall mean study drug compliance rate of 90.9% was comparable across treatment groups.
Efficacy
This study was designed to determine whether one or more doses of taranabant decrease body weight more than placebo in obese and overweight patients. Taranabant (0.5, 1 and 2 mg) produced significantly greater weight loss compared with placebo (Po0.001 vs placebo for all dose comparisons) as measured by change from baseline in body weight at week 52 (Table 4 , Figure 1a ). In all dose groups, progressive Taranabant Low-Dose Study J Proietto et al weight loss occurred with taranabant over the first 28-36 weeks, after which time body weight stabilized until week 52 without evidence of weight regain ( Figure 1a) . In contrast, patients in the placebo group achieved maximum weight loss by week 12 and showed evidence of weight regain by week 48. Treatment with all doses of taranabant also led to significantly greater reductions from baseline in waist circumference compared with placebo (Po0.001 vs placebo for all dose comparisons) shown in Table 4 .
The proportions of patients achieving at least 5% or greater weight loss at 52 weeks were significantly (Po0.001 vs placebo for all dose comparisons) higher in the taranabant 0.5-, 1-and 2-mg groups (44.2, 45.3 and 53.0%, respectively) compared with placebo (24.3%). Significantly (Po0.001 vs placebo for all dose comparisons) more patients in the taranabant groups also achieved a weight loss of at least 10% or greater at study endpoint compared with those in the placebo group (21.3, 18.2, 28.0 and 7.3% in the 0.5, 1, 2 mg Table 2 Demographics and baseline characteristics for patients randomized to placebo or taranabant 0.5, 1 and 2 mg The proportions shown in this column were calculated based on the number of randomized patients who took at least one dose of allocated treatment. One patient in the taranabant 0.5 mg group did not take any post-randomization study medication.
b Other reasons for discontinuation included patient moved (n ¼ 1), personal reasons (n ¼ 5) and other reasons (n ¼ 9).
c Other reasons for discontinuation included patient moved (n ¼ 8), pregnancy (n ¼ 1), personal reasons (n ¼ 1) and other reasons (n ¼ 5).
Taranabant Low-Dose Study J Proietto et al and placebo groups, respectively). A histogram of the weight loss and weight gain for placebo and each dose group of taranabant is shown in Figure 1b .
To determine whether obesity-related risk factors improved on taranabant compared with placebo, lipid-and glucose-related endpoints and blood pressure were assessed. From screening to randomization, which included 2 weeks of caloric restriction, patients experienced reductions of 10.6% in triglyceride, 6.7% in HDL-C, 9.8% in non-HDL-C, 9.4% in LDL-C and 8.4% in TC. Changes in lipid endpoints from baseline (at randomization) to week 52 are shown in Table 4 . In general, there were favorable trends in the lipid measures; however, changes by dose were not consistently significant.
Compared with placebo, nominally significant increases in plasma adiponectin were observed in the taranabant 1-mg and 2-mg groups and nominally significant decreases in high sensitivity C-reactive protein were observed in all taranabant groups. No significant improvement was observed with taranabant compared with placebo in fasting serum insulin, insulin sensitivity (QUICKI) or fasting plasma glucose (Table 4) .
Although both systolic and diastolic blood pressure were slightly reduced from baseline after 52 weeks of treatment with taranabant 0.5, 1 and 2-mg, the between-group differences were not statistically significant relative to placebo (Table 4) .
Validated questionnaires were incorporated into the study to assess the impact of weight and weight loss on the patients' quality of life. In general, treatment with taranabant did not affect any of the domains or components of the SF36/Acute v2 questionnaire with the exception of small improvements in the physical functioning domain seen with taranabant 0.5-mg compared with placebo (nominal P ¼ 0.013). The 0.5-and 2-mg groups showed an improvement in the physical function component as well as the total score of the IWQoL questionnaire compared with placebo (nominal Pp0.031 and Pp0.022, respectively), whereas the 2-mg group showed improvement on the public distress component relative to placebo (nominal P ¼ 0.033). All taranabant groups showed an improvement on the selfesteem component compared with placebo (nominal Pp0.040 for the taranabant groups).
Safety
The incidences of overall clinical adverse experiences in the taranabant 0.5, 1, 2-mg and placebo groups are shown in Table 5 . The percentages of patients with drug-related clinical adverse experiences and the percentage of patients discontinued due to a clinical adverse experience, or serious clinical adverse experience, in general, were numerically higher in the taranabant groups compared with the placebo group.
A summary of clinical adverse experiences at the system organ class (SOC) level occurring in at least 5% of patients in any treatment group is presented in Table 6 . The incidences of adverse experiences in the Gastrointestinal Disorders, General Disorders and Administrative Site Conditions, Nervous System Disorders and Psychiatric Disorders SOCs were numerically higher in the taranabant 1 and 2-mg groups compared with the placebo group. With the exception of the Gastrointestinal Disorders SOC where the Taranabant Low-Dose Study J Proietto et al Taranabant Low-Dose Study J Proietto et al incidence of adverse experiences was higher in the taranabant 0.5-mg group, the taranabant 0.5-mg group showed similar incidences of adverse experiences across the SOCs compared with the placebo group. The incidences of clinical adverse experiences determined by the investigator to be possibly, probably, or definitely related to study medication were higher in the taranabant groups compared with the placebo group with greater differences from placebo in the 1-and 2-mg groups (Table 5) . Table 6 provides a summary of drug-related clinical adverse experiences at the SOC level occurring in at least 2% of patients in any treatment group.
Relative to placebo, discontinuations due to total and drug-related clinical adverse experiences were higher in the taranabant groups with greater differences from placebo in the 1-and 2-mg groups (Table 5 ). Similar frequencies of discontinuations due to serious total clinical adverse experiences and serious drug-related clinical adverse experiences were reported in all groups ( Table 5 ). The most common drug-related clinical adverse experiences leading to study discontinuation were psychiatric-related adverse experiences where discontinuations were numerically higher in the taranabant group compared with the placebo group (Supplemental Information, Supplemental Table S1 ).
Analyses for the prespecified clinical adverse experiences are presented in Table 7 . Treatment with taranabant 1 and 2 mg was associated with a significantly higher incidence of psychiatric-related adverse experiences (Psychiatric Disorder SOC plus irritability SOC) compared with placebo. Treatment with taranabant at all doses was associated with a statistically significant higher incidence of irritability compared with placebo. Taranabant 2 mg was associated with a statistically higher incidence of aggression and anger; however, numerically higher incidences of these adverse experiences were also reported in the 0.5 and 1-mg groups, compared with the placebo group. Taranabant 2 mg was also associated with a statistically higher incidence of diarrhea, nausea, dizziness and flushing compared with placebo (Table 7) . There was one adverse experience of suicidal ideation in each of the taranabant groups and none in the placebo group. The frequencies of adjudicated suicidality were similar across the treatment groups.
Analyses of the change from baseline, after 52 weeks of treatment, for the POMSb total score and the 6 mood domains of the POMSb were conducted (Figure 2 ). Changes in total mood disturbance scores in all taranabant doses were not statistically different from placebo. However, statistically significant worsening of the anger-hostility domain occurred in all taranabant groups and a statistically significant worsening of the depression-dejection domain occurred in the 2-mg group relative to the placebo group. There was a statistically significant improvement in the vigor-activity score in the 0.5-mg group compared with the placebo group.
Mean baseline PHQ-9 scores were similar across the treatment groups (Supplemental Table S2 ). All treatment groups, including the placebo group, had small and similar increases in PHQ-9 scores (Supplemental Table S2 ). The proportion of patients with a maximum post-baseline PHQ-9 score in the minimal, mild, moderate, moderately severe and severe range in the taranabant groups was similar to the placebo group (Supplemental Table S2 ). The percentages of patients with a positive score for question 9 of the PHQ-9, which probes for suicidality, were low and similar across the treatment groups (data not shown). The incidences of laboratory adverse experiences were infrequent and comparable among the treatment groups ( Table 5 ). The specific laboratory adverse experiences were distributed across the laboratory test categories with no trend toward an increased incidence in the taranabant groups (data not shown). No serious laboratory adverse events were reported in this study and no patients discontinued treatment due to laboratory adverse experiences (Table 5 ). There were no clinically relevant changes in heart rate or QTc interval in any of the treatment groups. There were no consistent changes in mean laboratory test values for hematology or kidney or liver function tests across the treatment groups.
Discussion
This worldwide, multi-center, double-blind, randomized, placebo-controlled trial conducted in obese and overweight patients showed that treatment with taranabant 0. 5, 1 and 2 mg resulted in clinically meaningful weight loss that was superior to placebo at week 52. Statistical significance was reached for all of the pre-specified comparisons from the ordered family of primary comparisons: mean weight loss, the proportion of patients with at least 5% weight loss (5% responders), and the proportion of patients with at least 10% weight loss (10% responders). There was a dose-trend in weight loss efficacy, and for all taranabant groups, body weight decreased over time through week 36 after which time weight loss was maintained to the end of study (week 52). The magnitude of weight loss observed with taranabant 2 mg is consistent with what is observed in clinical trials of rimonabant 20 mg. [5] [6] [7] [8] [9] [10] Although, there was a suggestion of a dose-trend, the weight loss observed at week 52 in the lower dose groups was marginally lower, within 1.5 kg, than the 2 mg dose. The reduction in waist circumference relative to placebo, which was observed with all doses of taranabant at week 52, was consistent with the magnitude of weight loss and suggests a loss of visceral fat. Despite reductions in triglycerides observed during the 2-week diet/activity run-in period and considering that all treatment groups had normal mean triglycerides at baseline, a statistically significant median decrease in triglycerides was observed in the taranabant 1 and 2 mg groups compared with placebo at week 52. Increases in HDL-C at week 52 from randomization were observed in all treatment groups but the differences between taranabant groups and the placebo group were not statistically significant, suggesting no major weight-independent effect of the drug on the lipid profile.
No significant effect of taranabant was observed on blood pressure, fasting serum insulin, insulin sensitivity (QUICKI), or fasting plasma glucose. The absence of an effect on these measures in the setting of significant weight loss may be due to all treatment groups having normal values for these measures at baseline, or the degree of weight loss observed with taranabant compared with placebo was insufficient to detect a difference in these endpoints.
Because of known mechanism-based effects of CB1R antagonism on the gastrointestinal, psychiatric, nervous, skin and vascular systems, adverse experiences in these system organ classes were subject to inferential testing. In general, adverse experiences within the gastrointestinal, nervous, skin and vascular system organ classes were mild to moderate, resolved and did not lead to study drug discontinuation, suggesting that these treatment emergent adverse experiences were not a significant safety concern.
Adverse experiences within the Psychiatric Disorders SOC plus irritability were generally mild to moderate in intensity and predominately single episodes. Discontinuations due to drug-related clinical adverse experiences in the Psychiatric Disorders SOC plus irritability were generally higher in the taranabant groups. The absence of a significant difference in depression symptomatology identified by the PHQ-9 between the taranabant groups and the placebo group was Taranabant Low-Dose Study J Proietto et al consistent with the results from analyses of the prespecified adverse experiences in that the incidences of depressionrelated adverse experiences or suicidality-related adverse experiences were not significantly different between the taranabant groups (all doses) and placebo. However, for the POMSb, a statistically significant worsening of the depression-dejection domain was observed in the 2-mg group compared with the placebo group. Although, there was not a statistically significant increase in incidence of depressionrelated adverse experiences in the 2-mg group, other studies with taranabant 2, 4 and 6 mg have reported an increase incidence of depression-related adverse experiences. 11, 22 On the POMSb questionnaire, there was also a statistically significant worsening on the anger-hostility domain (which Table 6 System organ classes and clinical adverse experiences reaching an incidence of at least 5% and drug-related a clinical adverse experiences reaching an incidence of at least 2% in any treatment group Taranabant Low-Dose Study J Proietto et al includes adjectives like 'grouchy', 'annoyed', and 'ready to fight' that characterize irritability) in all taranabant treatment groups compared with placebo. This finding is consistent with the observation that the combined incidence of adverse experiences of aggression and anger were limited to patients in the taranabant groups and were significantly higher in the 2-mg group compared with the placebo group.
The incidences of psychiatric adverse experiences at the doses of taranabant used in this study appear lower than what was observed in other clinical studies with higher doses r Includes self reported suicidal ideation, and/or completed suicide, and/or suicide attempt, and/or preparatory acts toward imminent suicidal behavior, and/or positive responses to question 9/2i that relate to suicidal ideation on the PHQ-9/PHQ. Taranabant Low-Dose Study J Proietto et al of taranabant (4 and 6 mg) (see companion paper in this issue. 22 Nonetheless, even at the lowest dose tested (0.5 mg), psychiatric adverse experiences tended to be numerically higher compared with placebo. This indicates that psychiatric-related adverse experiences may be mechanismbased and not separable from weight loss. Similar psychiatric-related adverse experiences have been reported in published studies with the CB1R antagonist rimonabant, [5] [6] [7] [8] [9] [10] which further suggests these adverse experiences are mechanism-based. The relationship between taranabant-induced weight loss and drug-related adverse events cannot be established in this trial because of the following limitations. Patients with significant psychiatric adverse events tended to have onset in the first 4 weeks after randomization and certain psychiatric adverse events met prespecified discontinuation criteria. Thus, early discontinuation of drug therapy then limited drug exposure and subsequent drug-induced peak weight loss.
In conclusion, treatment with taranabant 0.5, 1 and 2 mg for 52 weeks led to clinically meaningful and statistically significant reductions in body weight and waist circumference in this study of obese and overweight patients. In general, incidences of gastrointestinal and psychiatric adverse experiences were dose-related. However, based on the risk/benefit profile of taranabant as observed in the entire Phase III program, Merck & Co. Inc. (Whitehouse Station, NJ, USA), discontinued the development of taranabant for the treatment of obesity.
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